Defining the molecular landscape of ependymomas

Tenley C Archer; Scott L Pomeroy

doi:10.1016/j.ccell.2015.04.015

Defining the molecular landscape of ependymomas

Cancer Cell. 2015 May 11;27(5):613-5. doi: 10.1016/j.ccell.2015.04.015.

Authors

Tenley C Archer¹, Scott L Pomeroy²

Affiliations

¹ Department of Neurology, Boston Children's Hospital, Harvard Medical School, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Harvard University, Cambridge, MA 02138, USA.
² Department of Neurology, Boston Children's Hospital, Harvard Medical School, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Harvard University, Cambridge, MA 02138, USA. Electronic address: scott.pomeroy@childrens.harvard.edu.

PMID: 25965568
DOI: 10.1016/j.ccell.2015.04.015

Abstract

Ependymomas have a variable prognosis. In this issue of Cancer Cell, Pajtler and colleagues identify nine subgroups of ependymoma using DNA methylation profiles. Two subgroups, predominately pediatric, are responsible for most of the mortality, with all others having nearly 100% overall survival after 5 years.

Publication types

Comment

MeSH terms

Age Factors*
Central Nervous System Neoplasms / pathology*
Ependymoma / pathology*
Female
Humans
Male